NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Sickle Cell Disease

, MD, PhD.

Author Information

Initial Posting: ; Last Revision: January 28, 2021.

Estimated reading time: 56 minutes


Clinical characteristics.

Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections. Acute chest syndrome is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation. Individuals with the highest rates of hemolysis are predisposed to pulmonary artery hypertension, priapism, and leg ulcers but may be relatively protected from vaso-occlusive pain.


SCD encompasses a group of disorders characterized by the presence of at least one hemoglobin S allele (HbS; p.Glu6Val in HBB) and a second HBB pathogenic variant resulting in abnormal hemoglobin polymerization. Hb S/S (homozygous p.Glu6Val in HBB) accounts for 60%-70% of SCD in the United States. Other forms of SCD result from coinheritance of HbS with other abnormal β-globin chain variants, the most common forms being sickle-hemoglobin C disease (Hb S/C) and two types of sickle β-thalassemia (Hb S/β+-thalassemia and Hb S/β°-thalassemia); rarer forms result from coinheritance of other Hb variants such as D-Punjab, O-Arab, and E.

The diagnosis of SCD is established by identification of significant quantities of HbS with or without an additional abnormal β-globin chain variant by hemoglobin assay or by identification of biallelic HBB pathogenic variants where at least one allele is the p.Glu6Val pathogenic variant (e.g., homozygous p.Glu6Val; p.Glu6Val and a second HBB pathogenic variant) on molecular genetic testing.

All states in the US have included newborn screening for SCD since 2005. Newborn screening programs perform isoelectric focusing and/or high-performance liquid chromatography (HPLC) of an eluate of dried blood spots. A few newborn screening programs confirm results with molecular testing.


Treatment of manifestations: Management of pain episodes includes hydration, anti-inflammatory agents, and pain medication. Pain episodes are additionally managed with a multimodel approach (e.g., warmth, massage, distraction, acupuncture, biofeedback, self-hypnosis). Fever and suspected infection is treated with appropriate antibiotics. Life-threatening or severe complications (e.g., severe acute chest syndrome, aplastic crisis, and stroke) are often treated with red blood cell transfusion. Splenectomy may be necessary for splenic sequestration. Severe priapism may require aspiration and irrigation.

Prevention of primary manifestations: Maintain hydration and avoid climate extremes. Chronic red blood cell transfusion in children at risk for stroke and individuals with pulmonary hypertension, chronic renal failure, recurrent acute chest syndrome, and severe end-organ damage. Hydroxyurea can decrease the frequency and severity of vaso-occlusive processes, reduce transfusion needs, and increase life span. Glutamine has received FDA approval for the prevention of acute complications in individuals with SCD age five years and older. Stem cell transplantation may be an option in selected individuals.

Prevention of secondary complications: Aggressive education on the management of fevers; prophylactic antibiotics, including penicillin in children; immunizations; folic acid supplementation; and iron chelation therapy for those with iron overload.

Surveillance: Periodic comprehensive medical and social evaluation, mental health and neurocognitive assessment, and routine dental care. Annual CBC and reticulocyte count, assessment of iron status, liver and renal function tests, urinalysis, LDH, and vitamin D level. Annual transcranial Doppler to determine risk of stroke in all children with Hb S/S and Hb S/β°-thalassemia and ophthalmologic evaluation in all with sickling disorders. There should be a low threshold to evaluate for end-organ damage including chest x-ray, EKG, abdominal ultrasound, and iron overload. Due to the high frequency and severity of cardiopulmonary complications there should be a particularly low threshold to obtain an echocardiogram, pulmonary function tests, and sleep study in individuals of any age with cardiac or pulmonary concerns.

Agents/circumstances to avoid: Dehydration, extremes of temperature, physical exhaustion, extremely high altitude, recreational drugs with vasoconstrictive or cardiac stimulation effects, and meperidine.

Evaluation of relatives at risk: Early diagnosis of at-risk family members allows education and intervention before symptoms or end-organ damage are present.

Pregnancy management: Women with SCD who become pregnant require close follow up and monitoring by a hematologist and obstetrician; an increased risk for preterm labor, thrombosis, infectious complications, and acute painful episodes has been reported during pregnancy; hydroxyurea should be discontinued during pregnancy.

Genetic counseling.

SCD is inherited in an autosomal recessive manner. If one parent is a carrier of the HBB HbS pathogenic variant and the other is a carrier of any of the HBB pathogenic variants (e.g., HbS, HbC, β-thalassemia), each child has a 25% chance of being affected, a 50% chance of being unaffected and a carrier, and a 25% chance of being unaffected and not a carrier. Carrier detection for common forms of SCD is most commonly accomplished by isoelectric focusing or HPLC. Prenatal and preimplantation genetic testing are possible if the HBB pathogenic variants have been identified in the parents.

GeneReview Scope

Included Disorders
  • Homozygous hemoglobin S alleles
    • Sickle cell disease (Hb S/S)
  • Coinheritance of one hemoglobin S allele and a second HBB pathogenic variant
    • Sickle-hemoglobin C disease (Hb S/C)
    • Sickle β-thalassemia (Hb S/β+-thalassemia and Hb S/β°-thalassemia)
    • Sickle-hemoglobin D, O, and E disease (or other beta globin chain variants)

For synonyms and outdated names see Nomenclature.


The term sickle cell disease (SCD) encompasses a group of disorders characterized by the presence of at least one hemoglobin S allele (HbS; p.Glu6Val in HBB) and a second HBB pathogenic variant resulting in abnormal hemoglobin polymerization. SCD (Hb S/S) caused by the homozygous HBB variant p.Glu6Val is the most common cause of SCD in the US. SCD caused by compound heterozygous HBB pathogenic variants includes sickle-hemoglobin C disease (Hb S/C) and two types of sickle β-thalassemia (Hb S/β+-thalassemia and Hb S/β°-thalassemia). Other beta globin chain variants such as D-Punjab, O-Arab, and E also result in SCD when inherited with HbS.

Suggestive Findings

While there is no single finding suggestive of sickle cell, the presence of the following features should raise suspicion, especially when both clinical and laboratory features are present in a person of sub-Saharan African, Indian, or Central American descent, or with a family history of SCD.

Clinical features

  • Infants with spontaneous painful swelling of the hands and feet
  • Recurrent episodes of severe pain with no other identified etiology
  • Unexplained anemia not related to iron deficiency
  • Pallor
  • Jaundice
  • Pneumococcal sepsis or meningitis
  • Severe anemia with splenic enlargement
  • Stroke, especially in a child

Note: Most individuals with SCD are healthy at birth and become symptomatic later in infancy or childhood after fetal hemoglobin levels decrease.

Laboratory features

  • Normocytic anemia
  • Sickle cells, nucleated red blood cells, target cells, and other abnormal red blood cells on peripheral blood smear; Howell-Jolly bodies indicate hyposplenism.
  • Presence of hemoglobin S (HbS) on a hemoglobin assay (e.g., high-performance liquid chromatography [HPLC], isoelectric focusing, cellulose acetate electrophoresis, citrate agar electrophoresis) with an absence or diminished amount of HbA

(For information about advantages and disadvantages of various hemoglobin assays, click here.)

Newborn screening. Newborn screening programs perform isoelectric focusing and/or HPLC of an eluate of dried blood spots. A few newborn screening programs confirm results with molecular testing (see Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up).

  • The normal newborn screening result is "FA" (i.e., more fetal hemoglobin (HbF) compared to adult hemoglobin [HbA]). Note: Hemoglobins identified by newborn screening are reported in order of quantity.
  • Specimens with "FS" are retested using a second confirmatory technique (e.g., HPLC, citrate agar electrophoresis, isoelectric focusing, or DNA-based assay).
  • Infants with hemoglobins that suggest SCD require additional confirmatory testing of a separate blood sample by age six weeks (see Table 1).

Establishing the Diagnosis

The diagnosis of SCD is based on the evaluation of adult hemoglobins (HbA, HbS, and other beta globin variants [e.g., HbC, HbE]). Fetal hemoglobin (HbF) is normally the predominant hemoglobin in newborns and decreases over the first year of life.

  • Identification of HbS as the sole adult beta chain on Hb assay indicates either Hb S/S or Hb S/β°-thalassemia. These can be distinguished by molecular testing, the combination of hemoglobin testing and other clinical studies, or in combination with family history.
  • S/β°-thalassemia and S/β+-thalassemia are distinguished by the presence of HbA in individuals with S/β+-thalassemia, but HbA is below that observed in sickle cell trait.
  • Identification of HbS and an additional beta-chain variant (e.g., HbC, D, O, or E) on Hb assay can establish the diagnosis in individuals who are compound heterozygous for specific HBB pathogenic variants (e.g., Hb S/C, Hb S/D, Hb S/O, Hb S/E).

Table 1.

Sickle Cell Disease: Diagnostic Test Results

Abnormal Globin β-Chain Variants 1Hemoglobins Identified by Age 6 Weeks 2PhenotypeHematologic Studies by Age Two Years
MCV 3, 4Hb A2 5
S/S (βSβS)HbF, HbSHemolysis and anemia by age 6-12 monthsN<3.6%
S/β°-thal (βSβ°)>3.6% 6
S/β+-thal (βSβ+)HbF, HbS, HbAMilder hemolysis and anemia
N or ↓
>3.6% 6
S/C (βSβC)HbF, HbS, HbC<3.6%

Table shows typical results; exceptions occur. Less common genotypes (e.g., SD, SOArab, SCHarlem, Lepore, and E) are not included.

↑ = increased; ↓ = decreased; MCV = mean corpuscular volume; N = normal; thal = thalassemia


The β-thalassemias are divided into β+-thalassemia, in which reduced levels of normal β-globin chains are produced, and β°-thalassemia in which there is no β-globin chain synthesis.


Hemoglobins reported in order of quantity (e.g., F, S, A = F>S>A)


Normal MCV: ≥70 at 6-12 months; ≥72 at 1-2 years; ≥81 in adults


Interpretation can be difficult as coexisting iron deficiency and alpha-thalassemia are common in SCD and can also reduce the MCV.


HbA2 results vary somewhat depending on laboratory method.


HbS with coexistent β-thalassemia causes ↓MCV and often leads to an HbA2 >3.6%.

Molecular genetic testing approaches can include single-gene testing and use of a multigene panel:

  • Single-gene testing. Sequence analysis of HBB is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found on sequence analysis.
  • A multigene panel that includes HBB and other genes of interest (see Differential Diagnosis) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
    For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

Table 2.

Molecular Genetic Testing Used in Sickle Cell Disease

Gene 1MethodProportion of Alleles with Pathogenic Variants 2 Detectable by Method
HBB Sequence analysis 3, 4100%
Gene-targeted deletion/duplication analysis 5See footnote 6.

See Molecular Genetics for information on allelic variants detected in this gene.


Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.


Note: All affected individuals would have at least one copy of the p.Glu6Val allele. Targeted assays for p.Glu6Val (HbS), p.Glu6Lys (HbC), p.Glu121Gln (HbD), p.Glu26Lys (HbE), and p.Glu121Lys (HbO) may be available (see Molecular Genetics).


Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.


While deletions or duplications will not result in a sickle pathogenic variant, gene deletions lead to a thalassemic allele which, if combined with a sickle cell pathogenic variant in trans configuration leads to S β°-thalassemia [Harteveld et al 2005].

Clinical Characteristics

Clinical Description

The clinical manifestations of sickle cell disease (SCD) result from intermittent episodes of microvascular occlusion leading to tissue ischemia/reperfusion injury and chronic hemolysis, both of which contribute to multiorgan dysfunction. The severity of disease manifestations varies, even in individuals with the same HBB pathogenic variants.

Vaso-occlusive events are associated with ischemia/reperfusion damage to tissues that lead to pain and acute or chronic injury affecting any organ system. The bones/marrow, spleen, liver, brain, lungs, kidneys, and joints are often affected. The biologic markers associated with this "vaso-occlusive phenotype" include the following [Darbari et al 2012, Wood et al 2012]:

  • A higher WBC count
  • A lower HbF level
  • Older age
  • Coexisting alpha-thalassemia trait
  • Iron overload (secondary to transfusions)
  • Vessel flow resistance related to deoxygenation

Chronic hemolysis is associated with chronic anemia as well as vascular dysfunction [Morris 2011]. Individuals with the highest rates of hemolysis are at increased risk of developing pulmonary artery hypertension, priapism, and leg ulcers [Kato & Taylor 2010]. Biologic markers for this "hemolytic phenotype" include the following:

  • Elevated plasma levels of lactate dehydrogenase (LDH)
  • A low hemoglobin level
  • A high reticulocyte count

Complications related to vaso-occlusive events

  • Vaso-occlusive pain episodes are the most frequent cause of recurrent morbidity in individuals with SCD and account for the majority of SCD-related hospital admissions as well as school and work absences [Gill et al 1995]. Vaso-occlusion is due to multicellular aggregates that block blood flow in small blood vessels, depriving downstream tissues of nutrients and oxygen, resulting in tissue ischemia and tissue death in the affected vascular beds. Vaso-occlusion and ischemic tissue damage cause excruciating pain. Young children more often complain of pain in their extremities, whereas older individuals more commonly experience pain in the head, chest, abdomen, and back.
  • Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD and occurs in infants and children. The dorsa of the extremities are most often involved; one or all four extremities can be involved. Although immediate sequelae are rare, dactylitis has been implicated as a risk factor for severe disease [Miller et al 2000].
  • Splenic sequestration and infarction. Splenic sequestration occurs in 10%-30% of children with SCD, most commonly between age six months and three years, and may follow a febrile illness. Splenic sequestration is characterized by an acutely enlarging spleen with hemoglobin >2 g/dL below the affected individual's baseline value. Mild-to-moderate thrombocytopenia may also be present. Children with splenic sequestration may experience abdominal pain, nausea, vomiting, lethargy, or irritability. Blood transfusion may be required as severe splenic sequestration may progress rapidly to shock and death. Recurrent episodes (or difficult-to-manage acute episodes) may require splenectomy. Historically most children with Hb S/S or S/β°-thalassemia will have a dysfunctional spleen within the first year of life and complete auto-infarction and atrophy due to ischemia of the spleen by age five years, though this natural history may be altered by hydroxyurea and chronic transfusion therapy. This splenic dysfunction contributes to the increased risk of sepsis and infection.
  • Infection. Young children with SCD and splenic dysfunction are at high risk for septicemia and meningitis due to encapsulated bacteria including Streptococcus pneumonia, Neisseria meningiditis, and Haemophilus influenza. Vaccination programs and prophylactic penicillin have significantly decreased the incidence of these infections [Adamkiewicz et al 2003].
  • Individuals with SCD are also at increased risk for other infections such as osteomyelitis caused by Staphylococcus aureus or other organisms such as Salmonella species. Infectious agents implicated in acute chest syndrome include Mycoplasma pneumoniae, Chlamydia pneumoniae, and Streptococcus pneumonia, as well as viruses. Parvovirus remains an important cause of aplastic crisis. Indwelling central venous catheters confer a high risk of bacteremia in individuals with SCD [Chulamokha et al 2006, Zarrouk et al 2006].
  • Acute chest syndrome (ACS) is a complex process that can arise from multiple diverse etiologies. ACS is a major cause of mortality [Bakanay et al 2005]. Although the definition varies in the literature, the diagnosis typically is made by the presence of a new pulmonary infiltrate on chest radiography in a person with SCD. This is often in the presence of respiratory tract symptoms, chest pain, hypoxemia, and/or fever. ACS often develops in the setting of a vaso-occlusive episode or with other acute manifestations of SCD, frequently after two to three days of severe vaso-occlusive pain. ACS can progress rapidly (over several hours to days) to requiring intubation and mechanical ventilatory support. A high index of suspicion is indicated: the presenting signs and symptoms of ACS can be highly variable and affected individuals may have an initial normal physical examination [Morris et al 1999]. Multiple etiologies (e.g., fat emboli from bone marrow infarcts, pneumonia, pulmonary infarction, pulmonary embolus), often at the same time, can lead to acute chest syndrome [Mekontso Dessap et al 2011].

Neurologic complications in SCD include stroke, silent cerebral infarcts, cerebral hemorrhage, cerebral blood flow abnormalities including moyamoya disease, and cerebral microvascular disease. Up to 50% of individuals with SCD will manifest some degree of cerebrovascular disease by age 14 years [Bernaudin et al 2011].

  • Ischemic strokes, most often seen in children and older adults, are among the most catastrophic manifestations of SCD. Common presenting signs and symptoms include: hemiparesis, monoparesis, seizures, aphasia or dysphasia, cranial nerve palsies, and mental status changes. Overt strokes occur in as many as 11% of children with SCD, with the peak occurrence between ages two and nine years. Recurring strokes occur in 50%-70% of affected individuals within three years after the first event. Transfusion therapy instituted after the initial stroke significantly reduces this risk [Serjeant 2013]. Narrowing of cerebral vessels is a risk factor for stroke, and elevated flow velocity on transcranial Doppler (TCD) identifies most children at high risk [Adams et al 1998], allowing intervention prior to the development of stroke [DeBaun & Kirkham 2016].
  • Silent cerebral infarcts (SCI) occur in approximately 22%-35% of individuals with SCD [Bernaudin et al 2011]. Silent cerebral infarcts are lesions identified on cerebral imaging studies without known focal neurologic symptoms; however, such lesions may be associated with neurocognitive deficits [Schatz et al 2001] and an increased risk for overt stroke [Miller et al 2001]. Thus, a "silent infarct" should not be thought of as a clinically insignificant condition. Cerebral arterial stenosis is noted to be a risk factor for SCI but is not always reflected by increased TCD velocities due to multiple variables, which influence individual vessel velocities. Additionally, accuracy of TCD measurements in demonstrating intracranial stenosis has not been firmly established. Utilization of methods to identify increased risk of stroke due to SCI, such as MRI/MRA, are being studied [Arkuszewski et al 2014, DeBaun & Kirkham 2016].

Complications related to hemolysis. A hyper-hemolysis syndrome marked by an elevated LDH, low hemoglobin level, and low reticulocyte count is associated with leg ulcers, priapism, pulmonary artery hypertension, systemic hypertension, and platelet activation [Hebbel 2011]. Other consequences of hemolysis include: chronic anemia, jaundice, predisposition to aplastic crisis, and cholelithiasis. While those with the highest rates of hemolysis may experience fewer pain episodes, the overall mortality rate for this group of individuals may be higher [Hebbel 2011, Kato et al 2017].

Aplastic crisis is the temporary interruption of red blood cell production, typically due to human parvovirus B19 infection in children, resulting in an acute and potentially life-threatening anemia. Sickle red blood cells survive for only about seven to 12 days, compared to 100-120 days for normal red blood cells. Thus parvovirus B19 infection, which can interrupt red blood cell production for eight to ten days, can result in a drop of hemoglobin level of 1 g/dL per day, leading to life-threatening levels in individuals with SCD that may require red blood cell transfusion.

Pulmonary hypertension. Pulmonary artery hypertension (PAH) affects approximately 6%-35% of adults with SCD and can have profound consequences [Parent et al 2011]. Although a similar proportion of children with SCD have PAH as diagnosed by echocardiography, PAH does not appear to be associated with the same dire outcomes as in adults [Lee et al 2009, Liem et al 2009, Hebson et al 2015].

While many have defined PAH in SCD by an elevated tricuspid regurgitant jet velocity (TRV) on transthoracic echocardiography (TTE), subsequent studies using direct measurement of PAP (pulmonary arterial pressure) by right heart catheterization indicate that this may over-diagnose PAH [Parent et al 2011]. PAH in adults is associated with markedly increased mortality [De Castro et al 2008] and significant morbidity, including exercise intolerance [Sachdev et al 2011]. Risk factors for PAH include markers of increased hemolysis, such as elevated LDH [Kato et al 2006], markers of cardiac strain, such as elevated brain natriuretic peptide (BNP) [Machado et al 2006], and the presence of obstructive sleep apnea [Hebson et al 2015]. Some individuals are relatively asymptomatic in the early stages of PAH. The relevance of these factors in children is less clear.

Priapism is very common among males with SCD, with a mean age of onset of 15 years [Adeyoju et al 2002]. These painful, unwanted erections occur spontaneously, with nocturnal erections, or with fever and dehydration. Males may have episodes of stuttering (intermittent) priapism lasting fewer than two to four hours that are often recurrent and may precede a more severe and persistent episode. "Severe priapism" episodes are persistent; those lasting more than two to four hours need rapid intervention because prolonged priapism may result in permanent erectile tissue damage and impotence [Rogers 2005].

Other complications of SCD include: avascular necrosis (typically involving the femoral head or humerus), nephropathy, restrictive lung disease, cholelithiasis, retinopathy, cardiomyopathy, and delayed growth and sexual maturation. Individuals with hemoglobin SC disease are at particularly high risk for retinopathy [Powars et al 2002]. Cardiopulmonary complications represent a major mortality risk in adults [Fitzhugh et al 2010].

Individuals who receive frequent red blood cell transfusion can develop problems with iron overload, with tissue iron deposition potentially damaging the liver, lungs, and heart [Kushner et al 2001], and alloimmunization that may interfere with the ability to obtain fully matched units of blood for transfusion [Vichinsky et al 1990].

Life expectancy. Previously, median survival in the US for those with SCD was estimated at age 42 years for men and age 48 years for women [Platt et al 1994]; however, survival of a subset of individuals with SCD beyond age 55 or 60 years has been described, though morbidity remains high [Serjeant 2013]. In addition, some evidence shows a shift towards longer survival over the last 20 years, with a significant decrease in childhood deaths [Hassell 2010, Quinn et al 2010].

The main causes of death are infection, acute chest syndrome, pulmonary artery hypertension, and cerebrovascular events [Bakanay et al 2005]. Causes of death in children tend to differ from those in adults. Children have higher rates of death from infection and sequestration crises whereas adult mortality is secondary to chronic end-organ dysfunction, thrombotic disease, and treatment-related complications [Manci et al 2003].

Heterozygotes for HbS have hemoglobins A and S (Hb A/S) (also called sickle cell trait). Heterozygous individuals are not anemic and have normal red cell indices with hemoglobin S percentages typically near 40%. In regions of the world where malaria is endemic, Hb A/S confers a survival advantage in childhood malaria; this is thought to be a major selective pressure for persistence of the HbS pathogenic variant (p.Glu6Val).

The amount of HbS present is insufficient to produce sickling manifestations under most circumstances and, thus, these individuals are usually asymptomatic but are at risk for several complications [Key & Derebail 2010]:

  • Extremes of physical exertion, dehydration, and/or altitude can induce sickle cell vaso-occlusive events in some individuals with Hb A/S [Mitchell 2007]. Individuals with Hb A/S should maintain aggressive hydration during extreme physical exertion, with no formal activity restrictions recommended. There is increased awareness of the low but significant risks for pulmonary emboli, exertional rhabdomyolysis, and sudden death with extreme exertion in individuals with Hb A/S. This has led to the mandatory offering of testing to all NCAA Division I college athletes [Bonham et al 2010]. The full implications of this policy are unclear, and the role of genetic counseling in this setting is complex as there is debate about the impact and consequences of testing [Aloe et al 2011, Tarini et al 2012, Thompson 2013].
  • Splenic infarct at high altitudes, impaired renal concentrating abilities, and intermittent micro- and macroscopic hematuria can occur in some individuals with Hb A/S.
  • Renal medullary carcinoma is an extremely rare form of kidney cancer occurring almost exclusively in individuals with sickle cell trait [Goldsmith et al 2012] such that a high index of suspicion for this rare diagnosis should be given for individuals with sickle cell trait who present with hematuria.
  • HB A/S may be associated with an increased risk for venous thromboembolism [Austin et al 2007].
  • There has not been an association of sickle cell trait with avascular necrosis, stroke, leg ulcers, cholelithiasis, or end-stage renal disease [Goldsmith et al 2012, Naik et al 2017].

Genotype-Phenotype Correlations

Although a tremendous amount of individual variability occurs, individuals with Hb S/S and S/β°-thalassemia are generally more severely affected than individuals with Hb S/C or S/β+-thalassemia. Molecular and genetic factors that are responsible for this variability are being investigated [Steinberg & Adewoye 2006].

Individuals with Hb S/C have longer red cell life span and higher hemoglobin concentration associated with fewer vaso-occlusive pain episodes. Splenomegaly and the associated risk for splenic sequestration can persist well beyond early childhood. Proliferative retinopathy and avascular necrosis are more likely to develop than in those with other sickle hemoglobinopathies.

The presence of α-thalassemia may modify SCD severity (see Differential Diagnosis). In general, α-thalassemia improves red cell survival and decreases hemolysis in SCD. However, the clinical effect on SCD is unclear and can be variable including possible decreased complications arising from hemolysis and potentially increased complications from vaso-occlusive events [Steinberg 2005].


Historically in the US, the term "sickle cell anemia" was used to describe persons homozygous for HbS. With increased awareness of the broad spectrum of clinically significant sickle hemoglobinopathies with varying degrees of anemia, the trend has been to use the umbrella term "sickle cell disease." The term sickle cell disease should be followed by a detailed genotypic description for the individual (e.g., Hb S/S, Hb S/C, or S/β°-thalassemia).


The HbS allele is common in persons of African, Mediterranean, Middle Eastern, and Indian ancestry and in persons from the Caribbean and parts of Central and South America, but can be found in individuals of any ethnic background.

Among African Americans, the prevalence of sickle cell trait (Hb A/S) is about 10%, resulting in the birth of approximately 1100 infants with SCD (Hb S/S) annually in the US. Approximately one in every 300-500 African Americans born in the US has SCD; more than 100,000 individuals are estimated to have SCD (Hb S/S) [Hassell 2010].

The prevalence of HBB alleles associated with SCD is even higher in other parts of the world. In many regions of Africa, the prevalence of the HbS pathogenic variant (p.Glu6Val) is as high as 25%-35%, with an estimated 15 million Africans affected by SCD and 200-300,000 affected births per year worldwide [Aliyu et al 2008, Mousa & Qari 2010]. SCD accounts for as many as 16% of deaths of children younger than age five years in Western Africa [Neville & Panepinto 2011].

Differential Diagnosis

The following diagnoses may be considered in an individual presenting with clinical features of SCD who did not have access to newborn screening. Each of these conditions would be easily distinguished from SCD by the absence of HbS on hemoglobin assay:

  • Acute anemia
  • Hemolytic anemia
  • Legg-Calve-Perthes disease
  • Osteomyelitis
  • Septic arthritis


Evaluations Following Initial Diagnosis

To establish the extent of end-organ damage and needs in an individual diagnosed with sickle cell disease (SCD), the following evaluations are recommended if they have not already been completed:

  • Hematology consultation
  • Consultation with a clinical geneticist and/or genetic counselor

Additional evaluations vary with the age and clinical status of the individual:

  • Infants after 12 months should have baseline laboratory studies including the following:
    • CBC and reticulocyte count
    • Measurement of HbF (%)
    • Assessment of iron status
    • A thalassemia screen, which includes hemoglobin electrophoresis or HPLC and an inclusion body prep
    • Baseline vitamin D; renal and liver function tests
    • Extended red cell phenotyping so that antigen matched blood may be given if transfusion is urgently needed
  • During childhood HLA typing should be offered to the affected individual and all full biologically matched sibs.
  • Older individuals. See Surveillance.

Treatment of Manifestations

Lifelong comprehensive care is necessary to minimize morbidity, reduce early mortality, and maximize quality of life. See Published Guidelines / Consensus Statements.

Education of parents, caregivers, and affected individuals is the cornerstone of care:

  • Families must appreciate the importance of routine health maintenance visits, prophylactic medications, and early intervention for both acute and chronic complications.
  • Warning signs of acute illness such as fever, respiratory symptoms, pallor, lethargy, splenic enlargement, and neurologic changes must be reviewed regularly and must include education for the affected individual, as developmentally appropriate.
  • A systematic approach to pain management should be reviewed regularly. This includes identifying and reversing common triggers for sickle cell pain (and distinguishing it from other etiologies of pain), hydration, warmth, ambulation, distraction, and other comfort maneuvers. Initiation of NSAIDs and appropriate use of opiates should be reviewed.
  • All families should have a plan in place for 24-hour access to a medical facility that can provide urgent evaluation and treatment of acute illnesses such as fever, acute chest syndrome, splenic sequestration, and stroke.
  • Families should be provided baseline (steady state) laboratory values for purposes of comparison, as values often change during acute illness.

General management of specific problems [NHS 2010, Bender & Seibel 2012, Brousse et al 2014, Yawn et al 2014] includes the following:

  • Vaso-occlusive pain episodes (including dactylitis)
    • The initial focus should include the reversal of inciting triggers (e.g., cold, dehydration).
    • Pain episodes are optimally managed using a multimodel approach that may include warmth, hydration, massage, distraction, acupuncture, biofeedback, self-hypnosis, and pharmaceuticals.
    • Uncomplicated pain episodes may be managed at home with oral hydration and oral analgesics including nonsteroidal anti-inflammatory drugs (NSAIDs) and opiates.
    • More severe pain episodes require hospitalization and administration of parenteral fluids and analgesics in addition to adjunctive treatments such as massage and physical therapy.
    • Optimal analgesia is generally achieved with morphine (or other opiate) given around the clock by a patient-controlled analgesia device (PCA) or by continuous infusion.
    • NSAIDs (e.g., ketorolac, ibuprofen, naproxen) may be used to augment the analgesic effect of opiates. NSAIDs can also decrease inflammation, which is part of the pathophysiology.
    • Adequate but not excessive hydration with IV fluids should be provided to maintain euvolemia, and individuals should be monitored closely for the development of other complications such as acute chest syndrome (ACS), splenic sequestration, or opiate-induced constipation.
    • A thorough evaluation for infection, including blood culture, urine culture, and chest x-ray should be considered based on the clinical scenario.
    Note: Transfusion and hydroxyurea are not useful treatments for acute pain episodes (see Prevention of Primary Manifestations).
  • Fever/suspected infection. Individuals with temperature greater than 38.3° C or persistent temperature elevation above baseline require:
    • Rapid triage and physical assessment;
    • Urgent CBC and reticulocyte count;
    • Blood culture (and other cultures as clinically indicated) and a low threshold for chest x-ray when respiratory symptoms are present, as ACS can often present with a normal physical examination;
    • Parenteral broad-spectrum empiric antibiotics such as ceftriaxone pending culture results. A macrolide antibiotic should be added if pneumonia/ACS is a concern. Additional antibiotics should be added only for proven or suspected meningitis or other severe illness.
    Note: With the changing natural history of fever and sepsis in individuals with SCD in the US there is increasing evidence that empiric treatment with parenteral antibiotics without obtaining cultures may be appropriate for well-appearing, fully immunized children with fever <39 C; however, this work has not yet been replicated nor has it become accepted practice [Baskin et al 2013, Ellison et al 2015].
  • Acute chest syndrome (ACS). The index of suspicion for ACS should be high when individuals with SCD have fever, chest pain, or respiratory signs or symptoms. Given the high mortality associated with ACS, an aggressive multimodal treatment strategy should be initiated [Miller 2011]:
    • Perform chest x-ray examination.
    • Provide aggressive treatment with oxygen, analgesics, and antibiotics (including a macrolide).
    • Incentive spirometry should be encouraged.
    • Hypoxemia can progress to need for intubation and mechanical ventilatory support.
    • Blood transfusion may be required for those who are critically ill, have multilobar disease, or have progressive disease despite conservative therapy.
  • Aplastic crisis. Monitoring of hematocrit (both absolute and compared with the individual's baseline), reticulocyte count, and cardiovascular status are required. Blood transfusion may be necessary. Aplastic crisis caused by parvovirus B19 will often spontaneously resolve; however, if the reticulocyte count does not improve, intravenous gamma-globulin can be considered to assist in viral clearance. Any sibs or other close contacts with SCD should be monitored for red blood cell aplasia because the parvovirus is easily transmissible.
  • Splenic sequestration. Severe episodes of splenic sequestration may progress rapidly to cardiovascular collapse and death; thus, emergency red blood cell transfusion is indicated when signs of cardiovascular instability are present. Parents should be taught how to monitor for splenic enlargement and recognize symptoms of sequestration and when to seek medical attention. Individuals who experience multiple severe episodes of splenic sequestration may require splenectomy.
  • Pulmonary hypertension. Diagnostic criteria, as well as when and how to intervene, are becoming increasingly controversial [Hassell et al 2014, Klings et al 2014a, Klings et al 2014b, Hebson et al 2015]. Existing consensus guidelines are not fully accepted by experts in the field. Thus, discussion with local sickle cell and pulmonary hypertension experts should be used to guide care. The following general approach is reasonable:
    • Aggressive evaluation and treatment of additional etiologies contributing to pulmonary hypertension (e.g., thrombotic disease, obstructive sleep apnea)
    • Optimization of SCD-related therapy to stop progression (e.g., chronic transfusions, hydroxyurea, oxygen therapy if hypoxemic)
  • Stroke. Any history of an acute neurologic symptom or event warrants emergent evaluation including a CBC with reticulocyte count and a non-contrast brain CT examination. Cerebral hemorrhage requires immediate neurosurgical consultation. An MRI/MRA to define injury should be obtained as soon as available, but definitive treatment with exchange transfusion should never be delayed for these results.
    Treatment for children with acute ischemic stroke includes the following:
    • Monitor neurologic status and aggressively treat increased intracranial pressure and seizures, if present.
    • Exchange transfusion with the goal of decreasing HbS percentage to <30% of the total hemoglobin followed by a chronic transfusion program can significantly decrease repeat risk for stroke [Wang et al 2000]. Without continued therapy, as many as 60%-90% of individuals who have had a stroke have a second stroke within three years. Thus, in most individuals a preventive chronic transfusion protocol is initiated after a CNS event and continued indefinitely [Adams & Brambilla 2005] (see Prevention of Primary Manifestations).
    • Hydroxyurea has been studied as an alternative to transfusion therapy [Ware & Helms 2012]. While it does not provide the same protection as transfusion therapy, it may be an alternative for affected individuals who are unable to receive transfusion therapy (e.g., those living in limiting resource settings such as the Third World) or are difficult to transfuse due to alloimmunization [de Montalembert 2012].
      Chronic transfusion has been shown to reduce silent infarcts; however, unlike for overt infracts, there is not a universally accepted consensus regarding the management of individuals with silent infarcts [DeBaun et al 2014, Estcourt et al 2017].
  • Priapism. Episodes of severe priapism require urgent evaluation and treatment, including hydration and analgesia, and may require aspiration and irrigation by an urologist.

Prevention of Primary Manifestations

Ongoing education is essential to help minimize morbidity and mortality. Education comprises a regular review of interventions including the following:

  • Maintaining hydration and avoiding extremes of climate
  • Monitoring for signs and symptoms requiring acute medical intervention
  • Early detection of chronic complications
  • Updates on new therapies

Disease-modulating therapies are discussed in several reviews [Vichinsky 2012, Kassim & DeBaun 2013, Ware et al 2017].

Chronic red blood cell transfusion therapy. The initial goal of chronic red blood cell transfusion therapy varies depending on indication but typically is to maintain the percentage of HbS <30% and suppress reticulocytosis. Chronic red blood cell transfusion therapy may be warranted for the following [Yawn et al 2014, Howard 2016, Ware et al 2017]:

  • Primary prevention of stroke in individuals with an abnormal transcranial Doppler
  • Prevention of stroke recurrence
  • Treatment of chronic pain refractory to other therapies
  • Pulmonary hypertension
  • Chronic renal failure
  • Recurrent episodes of ACS
  • Severe end-organ damage

Complications of chronic red blood cell transfusion therapy include: iron overload, alloimmunization, and, rarely, infection. To limit alloimmunization and transfusion reactions, extended matching of red blood cell antigens should be performed and blood products should be leuko-reduced (removal of white blood cells from the transfusion product). Red blood cells antigen matched at the full Rh locus (D, C, E) and Kell have been suggested to decrease alloimmunization rates, as well as other alleles when possible [Lasalle-Williams et al 2011]. Approaches to decrease alloimmunization in the future include obtaining a better understanding of the process of alloimmunization as well as molecular genotyping. Defining antigens molecularly has multiple benefits including the ability to type cells when serologic reagents are not available [Yazdanbakhsh et al 2012, Matteocci & Pierelli 2014].

Hydroxycarbamide (hydroxyurea), until recently the only FDA-approved therapy for SCD, is only approved for adults. Hydroxyurea benefits individuals with SCD via several mechanisms [Platt 2008, Ware 2010] including:

  • Induction of HbF synthesis resulting in decreased sickling and improved red-cell survival;
  • Reduction of white blood cell (WBC), reticulocyte and platelet counts;
  • Metabolism into nitric oxide, a potent vasodilator;
  • Overall improvement in blood flow;
  • Reduction of vascular inflammation.

Multiple NIH consensus statements have noted strong evidence to support its routine use in adults [Brawley et al 2008, Yawn et al 2014]. It has been demonstrated that hydroxyurea therapy is safe to use in children as young as nine months with no decrease in immune function [Ware 2010, Rogers et al 2011, Wang et al 2011, Strouse & Heeney 2012, Lederman et al 2014]. It is now very strongly recommended that every individual with S/S and S/β0-thalassemia age nine months or older be offered treatment with hydroxyurea [Yawn et al 2014]. This early initiation decreases clinical events [Thornburg et al 2012]. In addition, use of hydroxyurea has been associated with a decrease in healthcare costs [Wang et al 2013].

Hydroxyurea can have potentially significant toxicity, including myelosuppression. Individuals treated with hydroxyurea must be monitored closely with CBCs and reticulocyte counts. In order to balance the benefits with potential toxicities of hydroxyurea, many suggest a careful titration of the drug to find a dosing for each affected person that provides an appropriate reduction in WBC count without toxicity [Ware 2010, Strouse & Heeney 2012, Yawn et al 2014].

Glutamine has just received FDA approval for the prevention of acute complications in individuals age five years and older with SCD, whether on hydroxyurea or not. Due to its antioxidant properties and in vitro activity, glutamine has long been considered of potential benefit in the treatment of SCD. Though not published, a multicenter placebo-controlled clinical trial suggests that chronic use of oral glutamine can decrease the frequency of sickle cell pain-related episodes ( Having a second FDA-approved drug opens the door to combination therapy using multiple agents.

Stem cell transplantation from a healthy donor or one with sickle cell trait can be curative in individuals with SCD and while the number of matched-sib transplants continues to rise, there is rapid evolution in the use of alternate donors. Children with SCD receiving stem cell transplantation using a matched sib donor can expect a 92% chance of cure with an overall survival of 95%. [King & Shenoy 2014, Nickel et al 2014, Walters 2015]. These phenomenal outcomes are balanced by potential long-term consequences including chronic-graft-versus host disease and infertility. There is debate now as to who should be transplanted and when. Transplanting with a matched sib early in life can subvert a life of debilitating complications and decreasing end-organ function – the latter making transplant at a later age more difficult. Notably, pediatric providers may overly worry about the risks of transplant, while not appreciating the high morbidity of sickle cell disease manifestations in adulthood. However, the comparative long-term benefits of supportive care (including hydroxyurea and improvements in sickle cell management) versus transplantation are not yet known.

Despite the great successes associated with transplantation, it is estimated that fewer than 30% of individuals with SCD have suitable matched-sib donors, few have suitable matched unrelated donors, and transplant for adults with SCD has been far more difficult due to regime-related toxicity. The field of transplantation for SCD is currently undergoing rapid expansion. Thus, the use of alternate donors (including unrelated donors and haploidentical donors) and cord blood is an active area of research [Alfraih et al 2016, Arnold et al 2016, Walters et al 2016].

Initial myeloablative regimes yielded too much toxicity for older individuals with SCD; the recent development of less toxic transplant regimens makes stem cell transplantation a more acceptable option for older individuals [Tisdale et al 2013].

While unrelated cord blood transplants are falling out of favor due to the high rate of graft failure, there is an increased use and success of haploidentical transplants, vastly broadening the number of individuals who could potentially be cured [Gluckman 2013, Tisdale et al 2013, Walters 2015, Alfraih et al 2016, Arnold et al 2016].

Gene therapy. As all allogenic transplants for SCD present a risk for graft-versus-host disease, there has been an explosion of research in gene therapy for SCD. While both gene editing and gene addition approaches are being activity pursued, only viral mediated gene therapy approaches are being used in clinical trials [Goodman & Malik 2016, Cavazzana et al 2017].

The criteria, risks, and benefits of transplantation are changing rapidly; thus, it is important for families and providers to discuss the risks and benefits with a transplantation center with expertise in SCD.

Prevention of Secondary Complications

Newborn screening has made presymptomatic diagnosis possible, allowing for early, aggressive education on management issues, such as management of fevers. The use of prophylactic penicillin, immunization, and education emphasizing access to healthcare have significantly decreased morbidity and mortality in children, primarily by reducing deaths from sepsis.

Penicillin prophylaxis prevents 84% of life-threatening episodes of childhood Streptococcus pneumoniae sepsis [Gaston et al 1986]:

  • By age two months, all infants with SCD should receive penicillin V potassium prophylaxis, 125 mg orally, twice a day.
  • At age three years, the dose is increased to 250 mg orally, twice a day, and then continued until at least age five years.

Prophylaxis for those allergic to penicillin can include erythromycin or azithromycin but care should be taken to avoid medications that alter metabolism and increase the risk of prolonged QTc syndrome [Gerber et al 2009].

Immunizations. Timely administration of vaccines is essential. Clinicians should follow the recommended vaccine schedule for functionally asplenic individuals, which includes additional vaccines such as the 23-valent pneumococcal polysaccharide vaccine, and an altered schedule for meningococcal vaccines. Persons with sickle cell are considered high priority for annual influenza vaccine [Yawn et al 2014].

Folic acid supplementation should be considered to support the increased RBC synthesis secondary to the high RBC turnover in sickle cell.

Iron overload. Individuals receiving prophylactic as well as chronic transfusions are at risk for iron overload and should be monitored closely, initially by tracking the amount of blood transfused and monitoring serum ferritin concentration. Those with high exposures or documented iron overload should have an assessment of organ iron accumulation. With its increasing availability and safety and the ability to assess iron in multiple organs while avoiding sampling bias, quantitative radiographic evaluation such as T2*-weighted MRI is increasingly replacing biopsy [Wood 2007]. The noninvasive nature of monitoring iron overload via MRI or SQUID has led to significant improvements in the outcome of individuals with iron overload [Coates 2014]. Both oral or subcutaneous iron chelation therapy are recommended for those with documented excessive tissue iron deposition, with patient acceptance and use of medications being the main limiting factor [Coates & Wood 2017].


Surveillance should be tailored to an individual's specific phenotype and clinical history; however, most individuals benefit from routine age-dependent screening to allow for early detection and treatment of end-organ damage [NHS 2010, Yawn et al 2014]. The following are general guidelines compiled from several sources. Recently NHLBI has released updated guidelines that readers are encouraged to review. See Published Guidelines / Consensus Statements.

Comprehensive medical and social evaluation. Affected individuals should be seen routinely for evaluation of risks, review of care plan, education, and assessment of growth and development. Social work assessment with emphasis on support, resources, and the impact of disease on lifestyle should be performed. Routine dental care is recommended.

Mental health and neurocognitive assessment. Periodic mental health screening for signs of depression, anxiety, and isolation should occur. Neurocognitive testing should be performed prior to school entry and repeated periodically to identify learning difficulties that may be related to silent cerebral infarcts as well as other factors.

Annual laboratory assessment should include the following:

  • CBC with differential and reticulocyte count
  • Assessment of iron status
  • Liver function tests (LFTs), BUN, serum creatinine, and urinalysis (UA)
  • LDH as a marker of hemolysis
  • Vitamin D level; may be indicated because of the high prevalence of deficiencies in this population

Baseline values should be given to parents for comparison during times of illness.

Extended red cell phenotyping should be done once to decrease risk of alloimmunization with transfusions.

Assessment of stroke risk. Historically more than 10% of young children with Hb S/S and Hb S/β°-thalassemia (as well as some others) had overt strokes. Yearly screening with transcranial Doppler (TCD) starting at age two years followed by initiation of chronic therapy for those with high-velocity blood flow has drastically decreased stroke incidence in SCD [Fullerton et al 2004]. Individuals with an abnormally high arterial blood flow velocity have a high rate of stroke, which can be prevented by chronic red blood cell transfusion therapy. Children with normal velocities require yearly reevaluation as a proportion of them convert to higher-risk velocities over time [Adams et al 2004]. Initial studies suggest that this approach is decreasing the incidence of overt stroke in individuals with SCD, but additional measure may be of benefit as well [Fullerton et al 2004, Jordan et al 2012, Webb & Kwiatkowski 2013].

End-organ evaluation. While there is a clear consensus for use of screening TCD starting at age two years through at least age 16 years, there is variability in recommendations for additional screening. The NHLBI [Yawn et al 2014] suggests screening for a proliferative retinopathy by an ophthalmologist starting age ten years, and additional screening based on clinical history that may include:

  • Chest x-ray examination
  • EKG
  • Pulmonary function tests (PFTs)
  • Abdominal ultrasound examination
  • Echocardiogram to determine the tricuspid regurgitant (TR) jet with consideration of right heart catheterization depending on symptoms
  • Six-minute walk test
  • Pulmonary function testing
  • Sleep study (to assess nighttime hypoxemia)
  • Iron overload by MRI

Agents/Circumstances to Avoid

Education for individuals with SCD involves learning how to control one's environment to minimize the chance of exacerbations. Environmental controls include avoiding the following:

  • Dehydration
  • Extremes of temperature (e.g., swimming in cold water, which can trigger a pain episode)
  • Physical exhaustion
  • Extremely high altitude without oxygen supplementation
  • Cocaine. While alcohol and illegal drugs are never endorsed, cocaine and its derivatives, with their vasoconstrictive and cardiac stimulation effects, are particularly dangerous drugs in the setting of SCD.
  • The analgesic meperidine, which should be avoided as first-line therapy because of potential CNS toxicity

Evaluation of Relatives at Risk

Early diagnosis of at-risk family members may allow intervention before symptoms are present.

If born in the United States, sibs affected with SCD are diagnosed by universal newborn screening soon after birth (at which time referral to a pediatric hematologist is appropriate). Many states also identify sickle cell trait on newborn screening.

If newborn screening data is not available for at-risk sibs, several diagnostic approaches can be considered.

  • If the HBB pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.
  • If the pathogenic variants in the family are not known, the gold standard is a combination of HPLC or isoelectric focusing combined with a CBC and reticulocyte count. As microcytosis helps guide interpretation of results, a measure of iron status such as a ZPP (zinc protoporphyrin) test or serum iron and TIBC (total iron binding capacity) is of benefit.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

Pregnancy complications in SCD can be minimized with close follow up and collaboration between hematology and obstetric teams [Naik & Lanzkron 2012]. Pregnancy in women with SCD involves increased risk for thrombosis, infectious complications, and acute painful episodes [Villers et al 2008, Naik & Lanzkron 2012, Alayed et al 2014, Costa et al 2015]. There is conflicting information as to whether the risks for preeclampsia, eclampsia, pre-term labor, and maternal death are increased [Villers et al 2008, Naik & Lanzkron 2012, Alayed et al 2014, Costa et al 2015]. The risk of pregnancy complications increases when access to prenatal care is limited, reinforcing the importance of close hematologic and obstetric follow up [Naik & Lanzkron 2012]. The benefits of a chronic transfusion program versus the use of "as-needed" transfusions has not been established [Okusanya and Oladapo 2016]. As hydroxyurea is recommended for (and increasingly used in) adults, the current recommendation is that it be discontinued during pregnancy. While reports of human infants exposed prenatally to hydroxyurea have not noted an increased risk of malformations, in experimental animal models hydroxyurea has been noted to lead to an increase in congenital anomalies. The role of chronic transfusions in lieu of hydroxyurea needs to be addressed.

More than 99% of births to women with SCD occurring after 28 weeks’ gestation are live births with normal Apgar scores [Smith et al 1996]. Several studies have reported increased rates of low birth weight and intrauterine growth retardation in babies born to women with SCD [Hassell 2005]. Attention to postnatal opiate withdrawal in the babies of mothers treated with high-dose opiates during pregnancy is warranted.

Infants with SCD are asymptomatic in the antenatal, perinatal, and immediate postnatal periods; they manifest disease symptoms when fetal hemoglobin production switches to adult hemoglobin.

Therapies Under Investigation

Currently only one drug – hydroxyurea – is FDA approved for SCD, and labeling does not include children. After decades of slow progress in the field, acknowledgment of the plethora of pathways modulating the severity of SCD has led to a diverse array of therapeutic agents that are being investigated [Archer et al 2015, Kato 2016].

Some examples emphasizing the diverse array of involved pathways and agents are listed below. The field is changing rapidly; refer to in the US and EU Clinical Trials Register in Europe for the status of current studies.

Prevention of HbS polymerization. Hemoglobin S polymerizes in the T (tense) conformation associated with de-oxygenation, but not the R (relaxed) conformation associated with oxygenation. Thus, small molecules that block the T-state or stabilize the R-state are being assessed in clinical trials [Oder et al 2016].

Decreasing adhesion to the endothelium. Adhesion of WBC to the endothelium of the microcirculation slows blood flow, increasing HbS polymerization and worsening SCD. Agents that decrease cell adherence without compromising immune function are being pursued. E- and P-selectin specific agents are being tested with one showing promising results in a Phase III trial [Zhang et al 2016, Ataga et al 2017].

  • Modifying inflammatory responses. Regadenoson is an adenosine A2A receptor agonist that modifies natural killer cell activity and has shown benefit in animal models. It has been evaluated in a Phase I study and a Phase II clinical trial is under way [Field et al 2013].
  • Antioxidants therapy. Multiple antioxidants are being studied. One, glutamine, is a key factor in determining red cell red-ox state and its level has been a marker of disease severity [Morris et al 2008b]. Results for a Phase III clinical trial of glutamine supplementation are pending.
  • Rejuvenation of nitric oxide (NO) stores. Arginine, the precursor of NO, has been studied in several contexts and a Phase II clinical trial has shown benefit in hospitalized people with sickle cell pain [Morris et al 2013]. As a result, arginine has been featured in multiple clinical trials.
  • Induction of fetal hemoglobin. Multiple pathways and factors associated with the high-level expression of the fetal hemoglobin genes (HBG1 and HBG2) have been identified and are currently targets for intervention [Perrine et al 2014, Lettre & Bauer 2016]. Representative pathways include LSD-1 inhibitors [Shi et al 2013, Cui et al 2015], thalidomide inhibitors (e.g., pomolidomide) [Dulmovits et al 2016], nuclear factor erythroid 2-related factor 2 inhibitors (e.g., tert-butylhydroquinone) [Macari & Lowrey 2011, Macari et al 2013], HDAC inhibitors [Okam & Ebert 2012], short-chain fatty acids (e.g., butyrate or valproic acid), and antimetabolites (e.g., 2’ deoxy 5’ azacytidine [decitabine]) [Saunthararajah et al 2008]. A promising approach to therapy is the development of inhibitors to the protein Bcl11a. Bcl11a was identified as an HbF cell quantitative trait locus in a genome-wide association study [Menzel et al 2007]. Since then it has been shown to bind within the β-globin locus and to be critical for suppressing fetal globin gene expression in adult erythroid cells [Sankaran et al 2008, Sankaran et al 2010]. Knockdown or knockout of Bcl11a in model systems, as well as naturally occurring deletions that remove its binding site in humans, result in substantial increases in HbF. These elevated levels of HbF provide therapeutic benefits to individuals with both SCD and thalassemia [Sankaran et al 2011, Wilber et al 2011, Xu et al 2011]. Multiple approaches are being taken to inhibit Bcl11a function in vivo, including gene editing to disrupt the erythroid-specific enhancer of Bcl11a [Lettre & Bauer 2016]. Frangoul et al [2021] reported encouraging research results in the use of CRISPR/Cas9 technology to disrupt the BCL11A erythroid enhancer – and thereby induce γ-globin production – in an individual with sickle cell disease. One year post treatment, sustained production of γ-globin and elimination of vaso-occlusive events were reported in this individual.
  • Phytomedicines, including some mixtures of plants, are under investigation. There are initial promising safety and efficacy data for Niprisan® and SCD-101 [Oniyangi & Cohall 2015].

Gene therapy. As SCD arises from a defined single-nucleotide substitution in the β-globin gene whose expression is restricted to erythroid cells derived from bone marrow hematopoietic stem cells, SCD is an ideal candidate for gene therapy. Gene therapy provides the benefit of stem cell transplantation, but without the problems associated with the use of an allogenic source of stem cells. Ideally, gene therapy would lead to an increase in non-sickle β-like chains, while lowering the number of sickle chains, for example by replacing the HbS pathogenic variant (p.Glu6Val) with a normal allele.

The most progress has been made using viral vector-mediated addition of a normal β-like gene, potentially modified to have additional anti-sickling properties. This leaves the endogenous sickle allele intact. While multiple groups are moving towards these gene addition clinical trials, to date only one individual is reported to have been cured [Cavazzana et al 2017, Ribeil et al 2017]. The status of these trials is changing rapidly; refer to in the US and EU Clinical Trials Register in Europe for the most up-to-date information.

Multiple gene therapy strategies that do not involve the addition of an additional, therapeutic globin gene are being pursued. A major obstacle to the above gene addition approaches is the requirement for long-term, high-level expression of the therapeutic gene, which requires the inclusion of large amounts of the major regulatory element, the locus control region. In contrast, these approaches involve the transduction and stable integration of therapeutic reagent for which low-level expression suffices. These include:

  • Using transactivators to stimulate the minimally expressed delta gene or the fetal or embryonic genes;
  • Inducing embryonic α-like chains that, when forming tetramers with sickle chains, are less likely to polymerize;
  • Decreasing Bcl11a expression whether by knocking out erythroid regulatory elements or binding sites, knocking down mRNA, or altering protein interactions; and
  • Inducing "looping" between the locus control region and the fetal globin genes resulting in activation of HbF.

Some of the above approaches have the additional benefit of reducing expression of the sickle gene while increasing expression of a therapeutic gene. However, they require long-term expression, typically from a viral vector integrated into the genome, leading to the very real risk of severe sequelae, such as leukemia, stemming from insertional mutagenesis [Cavazza et al 2013]. These detriments of routine gene therapy are avoided by "gene editing." As multiple techniques to modify the human genome with base pair accuracy are becoming increasingly easy and efficient, gene editing approaches are being aggressively pursued [Scharenberg et al 2013, Kim & Kim 2014]. Gene editing typically entails the generation of a break in the DNA at or near the site of interest and the presence of a "corrective template." Fortuitously, the cell’s endogenous DNA repair machinery inadvertently uses the therapeutic template when repairing the DNA, resulting in the incorporation of the corrective sequence. Gene editing is a "hit and run" approach, as it can be performed with the transient expression of the editing tools, thus avoiding the need for long-term expression as well as the risk for insertional mutagenesis, yet providing lifelong correction of the DNA. Two major approaches are being taken: removal of the sickle pathogenic variant and replacement with a normal sequence; and disruption of regulators of globin gene expression – such as Bcl11a, which in turn results in increased expression of the fetal genes. As this can be done in hematopoietic as well as induced pleuripotent stem cells, gene editing is the future of gene therapy.

Search in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Sickle cell disease (SCD) is inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

  • The parents of an individual with Hb S/S are typically heterozygotes (i.e., carriers of at least one HbS pathogenic variant).
    It is possible that a parent is homozygous (i.e., Hb S/S) or is a compound heterozygote (e.g., Hb S/β°-thalassemia) rather than a heterozygote (Hb A/S).
  • The parents of an individual who is a compound heterozygote (e.g., Hb S/C or Hb S/β°-thalassemia) are typically heterozygous; one parent for HbS, and one parent for the other HBB pathogenic variant identified in the proband.
  • Heterozygotes (carriers) are generally asymptomatic, but may develop complications under extremes of physical exertion, dehydration, and/or altitude. There is increasing awareness of the risk for impaired renal concentrating abilities and microhematuria as well as an increased risk for venous thromboembolism in carriers of HbS as well as splenic infarcts, or sudden death associated with extreme conditions.

Sibs of a proband

  • If both parents are carriers of an HBB pathogenic variant, each sib of an affected individual has, at conception, a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.
  • If one parent is affected with SCD (i.e., is homozygous or compound heterozygous) and the other parent is heterozygous for an HBB pathogenic variant, each sib of an affected individual has a 50% chance of being affected and a 50% chance of being a carrier.
  • If both parents are affected with SCD (i.e., both parents are homozygous or compound heterozygous), all sibs of an affected individual will be affected.
  • Heterozygotes (carriers) are generally asymptomatic, but may develop complications under extremes of physical exertion, dehydration, and/or altitude. There is increasing awareness of the risk for complications such as impaired renal concentrating abilities and microhematuria, and increased risk for venous thromboembolism in carriers of HbS as well as splenic infarcts, or sudden death associated with extreme conditions.

Offspring of a proband

  • The offspring of an individual with SCD are obligate heterozygotes (carriers) for an HBB pathogenic variant.
  • If the reproductive partner of an affected individual is heterozygous for HbS or another sickle cell HBB pathogenic variant, each offspring will be at a 50% risk of having SCD.
  • If the reproductive partner of an individual with SCD is also affected with SCD, all offspring will have biallelic HBB pathogenic variants; the phenotype in these individuals will depend on their specific genotype (see Genotype-Phenotype Correlations).

Other family members

  • Each sib of the proband's parents is at a 50% or greater risk of being a carrier of an SCD-related HBB variant.
  • If one sib of a proband's parent is affected, each other (unaffected) sib of the proband's parent is at a 67% (2/3) risk of being a carrier.

Carrier (Heterozygote) Detection

If both SCD-related HBB pathogenic variants in a family are known, molecular genetic testing can be used to identify which at-risk family members are carriers.

If only one (or neither) SCD-related HBB pathogenic variant in a family is known, HPLC can be used to detect common HBB pathogenic variants involving qualitative abnormalities (i.e., abnormal hemoglobins). Note that HPLC may not always detect quantitative abnormalities such as thalassemias, which, when inherited with an HbS allele, result in a significant hemoglobinopathy; see Beta-Thalassemia for information on how to diagnose a coexisting thalassemia. Typical parental genotypes are described in Table 3.

Table 3.

Sickle Cell Disease: Parent and Proband Abnormal Globin β-Chain Variants

Abnormal Globin β-Chain Variants of the ProbandTypical Parental Globin β-Chain Variants 1
One ParentOther Parent
S/β°-thal 2A
N or ↑HbA2
N or ↑HbF
S/β+-thal 2

Table shows typical results; exceptions occur. Some rare globin β chain variants (e.g., S/D, S/OArab, S/CHarlem, Hb Lepore, S/E) are not included.

MCV = mean corpuscular volume ; N = normal; thal = thalassemia; ↑= increased; ↓= decreased


Assumes that uniparental disomy is absent and that both parents are heterozygous. Some parents may be homozygous or compound heterozygous.


HbA is detectable in individuals with β+-thalassemia but not S/β0-thalassemia or Hb S/C.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

It must be kept in mind that non-sickle β-globin disorders (e.g., β-thalassemia) can interact with the SCD-causing variant to cause clinically significant disease. As a result, family members without HbS can still have a child with a significant sickle hemoglobinopathy, which makes counseling difficult and leads to misconceptions in the community, and, on occasion, allegations of infidelity. For example, if one parent has sickle cell trait and the other has β-thalassemia trait, it would be correct to state that, although one parent is not a sickle cell carrier, there is still a 25% chance that each pregnancy would have a significant hemoglobinopathy. Therefore, partners of individuals who are known to be heterozygous for HbS should be offered a thalassemia screening panel that includes hemoglobin electrophoresis, CBC and reticulocyte count, and a measure of iron status (e.g., ZPP or serum iron and TIBC) to screen for carrier status for sickle cell trait and other β-globin disorders.

Family planning

  • The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

Early testing. Building community awareness of SCD in populations at high risk is an important component in facilitating early testing and receiving genetic counseling.

Cord blood banking. Given the (1) increasing safety and availability of stem cell transplantation in SCD and (2) limited number of immunologically matched donors available for individuals with SCD, it is appropriate to discuss sib cord blood banking with the parents of an affected individual.

DNA banking. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative genetic alteration/s are unknown).

Prenatal Testing and Preimplantation Genetic Testing

Once the HBB pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing for SCD are possible.

Because one parent may have a non-HbS HBB pathogenic variant that can interact with HbS to cause a sickle hemoglobinopathy (e.g., HbC or Hb β-thalassemia), both disease-causing HBB alleles of the carrier parents must be identified before prenatal testing can be performed.

Note: Because of the large variation in clinical course, currently it is not possible to accurately predict the severity of SCD in an individual.

When the mother is a known carrier and the father is unknown and/or unavailable for testing, options for prenatal testing can be explored in the context of formal genetic counseling.


GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • About Sickle Cell Disease
  • American Sickle Cell Anemia Association
    10300 Carnegie Avenue
    Cleveland OH 44106
    Phone: 216-229-8600
    Fax: 216-229-4500
  • California Sickle Cell Resources
  • My46 Trait Profile
  • National Library of Medicine Genetics Home Reference
  • NCBI Genes and Disease
  • Save Babies Through Screening Foundation, Inc.
    P. O. Box 42197
    Cincinnati OH 45242
    Phone: 888-454-3383
  • Sickle Cell Adult Provider Network
  • Sickle Cell Disease Association of America, Inc. (SCDAA)
    231 East Baltimore Street
    Suite 800
    Baltimore MD 21202
    Phone: 800-421-8453 (toll-free); 410-528-1555
    Fax: 410-528-1495
  • Sickle Cell Disease Foundation of California
    5777 West Century Boulevard
    Suite 1230
    Los Angeles CA 90045
    Phone: 310-693-0247
    Fax: 310-216-0307
  • Sickle Cell Disease National Resource Directory
  • Sickle Cell Information Center
  • Newborn Screening in Your State
    Health Resources & Services Administration
  • National Haemoglobinopathy Registry
    MDSAS NHR Administrator
    5 Union Street
    City View House
    Manchester M12 4JD
    United Kingdom
    Phone: 0161 277 7917

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

Sickle Cell Disease: Genes and Databases

Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.

Table B.

OMIM Entries for Sickle Cell Disease (View All in OMIM)


Gene structure. HBB, which spans 1.6 kb, contains three exons. HBB is regulated by an adjacent 5' promoter, which contains TATA, CAAT, and duplicated CACCC boxes, and an upstream regulatory element known as the locus control region (LCR). HBB is contained within the HBB gene cluster, which also includes the genes encoding the delta-globin chain, A gamma and G gamma chains, and HBBP1 (an HBB pseudogene) and epsilon. For a detailed summary of gene and protein information, see Table A, Gene.

Pathogenic variants. Sickle cell disease results from biallelic HBB pathogenic variants where at least one allele is the p.Glu6Val pathogenic variant (e.g., homozygous p.Glu6Val; p.Glu6Val and a second HBB pathogenic variant – see Table 4 for examples).

Table 4.

HBB Pathogenic Variants Discussed in This GeneReview

DNA Nucleotide Change 1Predicted Protein Change
(Standard Nomenclature 2)
Hb VariantReference
HbS NM_000518​.4

Variants listed in the table have been provided by the author. GeneReviews staff have not independently verified the classification of variants.

GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen​ See Quick Reference for an explanation of nomenclature.


DNA nucleotide changes follow current nomenclature guidelines where the number 1 corresponds to the first nucleotide of the initiating methionine.


In this column and throughout the text of the GeneReview, the protein amino acid changes (e.g., p.Glu6Val) follow the longstanding convention in the hemoglobin literature of beginning the numbering of amino acids at the second amino acid residue (Val) rather than the initiating Met. This convention was adopted many years ago because the initiating methionine is not part of the mature β-globin protein. The standard nomenclature for protein changes is given in parentheses. The Globin Gene Server (globin​ lists variants using both numbering conventions.

Normal gene product. HBB encodes the hemoglobin β chain. The normal heterotetrameric protein hemoglobin A (HbA) comprises two hemoglobin α chains, two hemoglobin β chains, and four heme moieties.

Abnormal gene product. Sickle hemoglobin (HbS) results specifically from the p.Glu6Val substitution. In deoxygenated sickle hemoglobin, an interaction between p.Val6 and the complementary regions on adjacent molecules results in the formation of highly ordered, insoluble molecular polymers that aggregate and distort the shape of red blood cells, making them brittle and poorly deformable, increasing adherence to the endothelium. This can lead to veno-occlusion, decreased tissue perfusion, and ischemia. While this is thought to be the proximate defect leading to several aspects of clinical disease, there is increasing awareness that multiple pathophysiologic pathways are involved in SCD [Zhang et al 2016, Kato et al 2017].

Polymerized hemoglobin is also injurious to the red cell membrane, resulting in cellular dehydration, oxidative damage, and increased adherence to endothelial cells [Gladwin & Rodgers 2000, Hebbel 2000, Nagel 2001] and chronic hemolysis.

Other factors contributing to the pathophysiology of sickle cell include: leukocytosis (resulting in increased production of injurious cytokines and altered blood flow), coagulation abnormalities, and abnormal vascular regulation. The net result of these abnormalities is shortened red cell life span or hemolysis and intermittent vascular occlusion and a state of chronic inflammation.

Chapter Notes

Author History

MA Bender, MD, PhD (2006-present)
Gabrielle Douthitt Seibel, MN, MPH, ARNP; Seattle Children’s Hospital (2014-2017)
William Hobbs, MD, PhD; Puget Sound Blood Center (2009-2014)
Krysta Schlis, MD; Children's Hospital Oakland (2003-2006)
Elliott Vichinsky, MD; Children's Hospital Oakland (2003-2006)

Revision History

  • 28 January 2021 (aa) Revision: use of CRISPR/Cas9 technology (Therapies Under Investigation)
  • 17 August 2017 (sw) Comprehensive update posted live
  • 23 October 2014 (me) Comprehensive update posted live
  • 17 May 2012 (mb) Revision: clarification of information regarding risk for renal medullary carcinoma in individuals with sickle cell trait
  • 9 February 2012 (me) Comprehensive update posted live
  • 17 September 2009 (cd) Revision: corrections to testing information (Table 2)
  • 6 August 2009 (me) Comprehensive update posted live
  • 7 March 2006 (me) Comprehensive update posted live
  • 15 September 2003 (me) Review posted live
  • 21 April 2003 (ev) Original submission


Published Guidelines / Consensus Statements

  • National Health Service. NHS Sickle Cell & Thalassaemia Screening Programme. Standards and Guidelines. Available online. Accessed 10-13-21.
  • National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. Available online. 2014. Accessed 10-13-21.

Literature Cited

  • Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong WY, Wang WC. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143:438–44. [PubMed: 14571216]
  • Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–78. [PubMed: 16382063]
  • Adams RJ, Brambilla DJ, Granger S, Gallagher D, Vichinsky E, Abboud MR, Pegelow CH, Woods G, Rohde EM, Nichols FT, Jones A, Luden JP, Bowman L, Hagner S, Morales KH, Roach ES, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood. 2004;103:3689–94. [PubMed: 14751925]
  • Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11. [PubMed: 9647873]
  • Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int. 2002;90:898–902. [PubMed: 12460353]
  • Alayed N, Kezouh A, Oddy L, Abenhaim HA. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. J Perinat Med. 2014;42:487–92. [PubMed: 24344096]
  • Alfraih F, Aljurf M, Fitzhugh CD, Kassim AA. Alternative donor allogeneic hematopoietic cell transplantation for hemoglobinopathies. Semin Hematol. 2016;53:120–8. [PubMed: 27000737]
  • Aliyu ZY, Kato GJ, Taylor J 6th, Babadoko A, Mamman AI, Gordeuk VR, Gladwin MT. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. Am J Hematol. 2008;83:63–70. [PubMed: 17910044]
  • Aloe A, Krishnamurti L, Kladny B. Testing of collegiate athletes for sickle cell trait: what we, as genetic counselors should know. J Genet Couns. 2011;20:337–40. [PubMed: 21503822]
  • Archer N, Galacteros F, Brugnara C. 2015 Clinical trials update in sickle cell anemia. Am J Hematol. 2015;90:934–50. [PMC free article: PMC5752136] [PubMed: 26178236]
  • Arkuszewski M, Krejza J, Chen R, Ichord R, Kwiatkowski JL, Bilello M, Zimmerman R, Ohene-Frempong K, Melhem ER. Sickle cell anemia: intracranial stenosis and silent cerebral infarcts in children with low risk of stroke. Adv Med Sci. 2014;59:108–13. [PubMed: 24797985]
  • Arnold SD, Bhatia M, Horan J, Krishnamurti L. Haematopoietic stem cell transplantation for sickle cell disease: current practice and new approaches. Br J Haematol. 2016;174:515–25. [PubMed: 27255787]
  • Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–39. [PMC free article: PMC5481200] [PubMed: 27959701]
  • Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007;110:908–12. [PubMed: 17409269]
  • Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005;105:545–7. [PubMed: 15454485]
  • Baskin MN, Goh XL, Heeney MM, Harper MB. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. Pediatrics. 2013;131:1035–41. [PubMed: 23669523]
  • Bender MA, Seibel G. Sickle cell disease critical elements of care. The Center for Children with Special Needs. Seattle Children’s Hospital, Seattle, WA. Available online. 2012. Accessed 10-13-21.
  • Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Coïc L, Leveillé E, Lemarchand E, Lesprit E, Abadie I, Medejel N, Madhi F, Lemerle S, Biscardi S, Bardakdjian J, Galactéros F, Torres M, Kuentz M, Ferry C, Socié G, Reinert P, Delacourt C. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117:1130–40. [PubMed: 21068435]
  • Bonham VL, Dover GJ, Brody LC. Screening student athletes for sickle cell trait--a social and clinical experiment. N Engl J Med. 2010;363:997–9. [PubMed: 20825310]
  • Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932–8. [PubMed: 18458271]
  • Brousse V, Makani J, Rees DC. Management of sickle cell disease in the community. BMJ. 2014;348:g1765. [PMC free article: PMC5612384] [PubMed: 24613806]
  • Cavazza A, Moiani A, Mavilio F. Mechanisms of retroviral integration and mutagenesis. Hum Gene Ther. 2013;24:119–31. [PubMed: 23330935]
  • Cavazzana M, Antoniani C, Miccio A. Gene Therapy for β-Hemoglobinopathies. Mol Ther. 2017;25:1142–54. [PMC free article: PMC5417842] [PubMed: 28377044]
  • Chulamokha L, Scholand SJ, Riggio JM, Ballas SK, Horn D, DeSimone JA. Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysis. Am J Hematol. 2006;81:723–8. [PubMed: 16795063]
  • Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radic Biol Med. 2014;72:23–40. [PMC free article: PMC4940047] [PubMed: 24726864]
  • Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017;177:703–16. [PMC free article: PMC5444974] [PubMed: 28295188]
  • Costa VM, Viana MB, Aguiar RA. Pregnancy in patients with sickle cell disease: maternal and perinatal outcomes. J Matern Fetal Neonatal Med. 2015;28:685–9. [PubMed: 24866352]
  • Cui S, Lim KC, Shi L, Lee M, Jearawiriyapaisarn N, Myers G, Campbell A, Harro D, Iwase S, Trievel RC, Rivers A, DeSimone J, Lavelle D, Saunthararajah Y, Engel JD. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood. 2015;126:386–96. [PMC free article: PMC4504950] [PubMed: 26031919]
  • Darbari DS, Onyekwere O, Nouraie M, Minniti CP, Luchtman-Jones L, Rana S, Sable C, Ensing G, Dham N, Campbell A, Arteta M, Gladwin MT, Castro O, Taylor JG 6th, Kato GJ, Gordeuk V. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr. 2012;160:286–90. [PMC free article: PMC3258348] [PubMed: 21890147]
  • DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699–710. [PMC free article: PMC4195437] [PubMed: 25140956]
  • DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127:829–38. [PubMed: 26758917]
  • De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83:19–25. [PubMed: 17724699]
  • de Montalembert M. To SWiTCH or not to SWiTCH? Blood. 2012;119:3870–1. [PubMed: 22538492]
  • Dulmovits BM, Appiah-Kubi AO, Papoin J, Hale J, He M, Al-Abed Y, Didier S, Gould M, Husain-Krautter S, Singh SA, Chan KW, Vlachos A, Allen SL, Taylor N, Marambaud P, An X, Gallagher PG, Mohandas N, Lipton JM, Liu JM, Blanc L. Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood. 2016;127:1481–92. [PMC free article: PMC4797024] [PubMed: 26679864]
  • Ellison AM, Thurm C, Alessandrini E, Jain S, Cheng J, Black K, Schroeder L, Stone K, Alpern ER. Variation in pediatric emergency department care of sickle cell disease and fever. Acad Emerg Med. 2015;22:423–30. [PubMed: 25779022]
  • Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2017;5:CD012389. [PMC free article: PMC5460750] [PubMed: 28500860]
  • Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 2013;121:3329–34. [PMC free article: PMC3637009] [PubMed: 23377438]
  • Fitzhugh CD, Lauder N, Jonassaint JC, Telen MJ, Zhao X, Wright EC, Gilliam FR, De Castro LM. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol. 2010;85:36–40. [PMC free article: PMC3865703] [PubMed: 20029950]
  • Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384:252–60. [PubMed: 33283989]
  • Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104:336–9. [PubMed: 15054044]
  • Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, Diamond S, Tate Holbrook C, Gill FM, Ritchey K, Falletta JM., Prophylactic Penicillin Study Group. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314:1593–9. [PubMed: 3086721]
  • Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009;119:1541–51. [PubMed: 19246689]
  • Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86:776–83. [PubMed: 7606007]
  • Gladwin MT, Rodgers GP. Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet. 2000;355:1476–8. [PubMed: 10801164]
  • Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013:370–6. [PubMed: 24319206]
  • Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol. 2012;87:340–6. [PMC free article: PMC3513289] [PubMed: 22307997]
  • Goodman MA, Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. Ther Adv Hematol. 2016;7:302–15. [PMC free article: PMC5026290] [PubMed: 27695619]
  • Harteveld CL, Voskamp A, Phylipsen M, Akkermans N, den Dunnen JT, White SJ, Giordano PC. Nine unknown rearrangements in 16p13.3 and 11p15.4 causing alpha- and beta-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. J Med Genet. 2005;42:922–31. [PMC free article: PMC1735959] [PubMed: 15894596]
  • Hassell K. Pregnancy and sickle cell disease. Hematol Oncol Clin North Am. 2005;19:903–16. [PubMed: 16214651]
  • Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38:S512–21. [PubMed: 20331952]
  • Hassell KL, Afenyi-Annan A, Ballas SK, Buchanan GR, Eckman JR, Jordan L, Lanzkron S, Lottenberg R, Ware R. Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. Am J Respir Crit Care Med. 2014;190:237–8. [PubMed: 25025359]
  • Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med. 2000;342:1910–2. [PubMed: 10861330]
  • Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86:123–54. [PubMed: 21264896]
  • Hebson C, New T, Record E, Oster M, Ehrlich A, Border W, James-Herry A, Kanaan U. Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predictive than previously thought? J Pediatr Hematol Oncol. 2015;37:134–9. [PubMed: 24942020]
  • Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016;2016:625–31. [PMC free article: PMC6142434] [PubMed: 27913538]
  • Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol. 2012;157:14–25. [PMC free article: PMC3400704] [PubMed: 22224940]
  • Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. Annu Rev Med. 2013;64:451–66. [PubMed: 23190149]
  • Kato GJ. New insights into sickle cell disease: mechanisms and investigational therapies. Curr Opin Hematol. 2016;23:224–32. [PMC free article: PMC4969007] [PubMed: 27055046]
  • Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107:2279–85. [PMC free article: PMC1895723] [PubMed: 16291595]
  • Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127:750–60. [PMC free article: PMC5330745] [PubMed: 28248201]
  • Kato GJ, Taylor JG 6th. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol. 2010;148:690–701. [PMC free article: PMC3210728] [PubMed: 19958359]
  • Key NS, Derebail VK. Sickle-cell trait: novel clinical significance. Hematology Am Soc Hematol Educ Program. 2010;2010:418–22. [PMC free article: PMC3299004] [PubMed: 21239829]
  • Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15:321–34. [PubMed: 24690881]
  • King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123:3089–94. [PubMed: 24511087]
  • Klings ES, Machado RF, Morris CR, Gordeuk VR, Kato GJ, Ataga KI, Castro O, Hsu L, Telen MJ, Krishnamurti L, Steinberg MH, Gladwin MT., ATS Clinical Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease Committee. Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. Am J Respir Crit Care Med. 2014a;190:238–40. [PMC free article: PMC4226058] [PubMed: 25025360]
  • Klings ES, Morris CR, Hsu LL, Castro O, Gladwin MT, Mubarak KK. Pulmonary hypertension of sickle cell disease beyond classification constraints. J Am Coll Cardiol. 2014b;63:2881–2. [PubMed: 24794120]
  • Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001:47–61. [PubMed: 11722978]
  • Lasalle-Williams M, Nuss R, Le T, Cole L, Hassell K, Murphy JR, Ambruso DR. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011;51:1732–9. [PubMed: 21332724]
  • Lederman HM, Connolly MA, Kalpatthi R, Ware RE, Wang WC, Luchtman-Jones L, Waclawiw M, Goldsmith JC, Swift A, Casella JF, et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics. 2014;134:686–95. [PMC free article: PMC4179098] [PubMed: 25180279]
  • Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham GM. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. Br J Haematol. 2009;146:437–41. [PMC free article: PMC3078564] [PubMed: 19563512]
  • Lettre G, Bauer DE. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. Lancet. 2016;387:2554–64. [PubMed: 27353686]
  • Liem RI, Nevin MA, Prestridge A, Young LT, Thompson AA. Functional capacity in children and young adults with sickle cell disease undergoing evaluation for cardiopulmonary disease. Am J Hematol. 2009;84:645–9. [PubMed: 19705433]
  • Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood. 2011;117:5987–97. [PMC free article: PMC3112042] [PubMed: 21464371]
  • Macari ER, Schaeffer EK, West RJ, Lowrey CH. Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Blood. 2013;121:830–9. [PMC free article: PMC3563366] [PubMed: 23223429]
  • Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, Taveira-DaSilva AM, Ballas SK, Blackwelder W, Xu X, Hunter L, Barton B, Waclawiw M, Castro O, Gladwin MT, Investigators MSH. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296:310–8. [PubMed: 16849664]
  • Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN., Investigators of the Cooperative Study of Sickle Cell Disease. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359–65. [PubMed: 14531921]
  • Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang. 2014;106:197–208. [PubMed: 24117723]
  • Mekontso Dessap A, Deux JF, Abidi N, Lavenu-Bombled C, Melica G, Renaud B, Godeau B, Adnot S, Brochard L, Brun-Buisson C, Galacteros F, Rahmouni A, Habibi A, Maitre B. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011;184:1022–9. [PubMed: 21836136]
  • Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, Foglio M, Zelenika D, Boland A, Rooks H, Best S, Spector TD, Farrall M, Lathrop M, Thein SL. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39:1197–9. [PubMed: 17767159]
  • Miller ST. How I treat acute chest syndrome in children with sickle cell disease. Blood. 2011;117:5297–305. [PubMed: 21406723]
  • Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83–9. [PubMed: 10631276]
  • Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, Styles L, Adams RJ. STOP Investigators. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139:785–9. [PubMed: 11743502]
  • Mitchell BL. Sickle cell trait and sudden death--bringing it home. J Natl Med Assoc. 2007;99:300–5. [PMC free article: PMC2569637] [PubMed: 17393956]
  • Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? Ann Emerg Med. 1999;34:64–9. [PubMed: 10381996]
  • Morris CR. Vascular risk assessment in patients with sickle cell disease. Haematologica. 2011;96:1–5. [PMC free article: PMC3012755] [PubMed: 21193426]
  • Morris CR, Kuypers FA, Lavrisha L, Ansari M, Sweeters N, Stewart M, Gildengorin G, Neumayr L, Vichinsky EP. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98:1375–82. [PMC free article: PMC3762093] [PubMed: 23645695]
  • Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008b;111:402–10. [PMC free article: PMC2200820] [PubMed: 17848621]
  • Mousa SA, Qari MH. Diagnosis and management of sickle cell disorders. Methods Mol Biol. 2010;663:291–307. [PubMed: 20617425]
  • Nagel RL. Pleiotropic and epistatic effects in sickle cell anemia. Curr Opin Hematol. 2001;8:105–10. [PubMed: 11224685]
  • Naik RP, Irvin MR, Judd S, Gutiérrez OM, Zakai NA, Derebail VK, Peralta C, Lewis MR, Zhi D, Arnett D, McClellan W, Wilson JG, Reiner AP, Kopp JB, Winkler CA, Cushman M. Sickle cell trait and the risk of ESRD in blacks. J Am Soc Nephrol. 2017;28:2180–7. [PMC free article: PMC5491293] [PubMed: 28280138]
  • Naik RP, Lanzkron S. Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2012;2012:208–14. [PubMed: 23233583]
  • Neville KA, Panepinto JA. Pharmacotherapy of sickle cell disease. 18th Expert Committee on the Selection and Use of Essential Medicines. Available online. 2011. Accessed 10-13-21.
  • NHS. Sickle cell disease in childhood: Standards and guidelines for clinical care (pdf). Available online. 2010. Accessed 10-13-21.
  • Nickel RS, Hendrickson JE, Haight AE. The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe" sickle cell disease. Blood. 2014;124:861–6. [PubMed: 24963044]
  • Oder E, Safo MK, Abdulmalik O, Kato GJ. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br J Haematol. 2016;175:24–30. [PMC free article: PMC5035193] [PubMed: 27605087]
  • Okam MM, Ebert BL. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Expert Rev Hematol. 2012;5:303–11. [PubMed: 22780210]
  • Okusanya BO, Oladapo OT. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database Syst Rev. 2016;12:CD010378. [PMC free article: PMC6463955] [PubMed: 28005272]
  • Oniyangi O, Cohall DH. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database Syst Rev. 2015;(4):CD004448. [PubMed: 25844571]
  • Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Yaïci A, Hajji L, O'Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365:44–53. [PubMed: 21732836]
  • Perrine SP, Pace BS, Faller DV. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. Hematol Oncol Clin North Am. 2014;28:233–48. [PubMed: 24589264]
  • Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358:1362–9. [PubMed: 18367739]
  • Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44. [PubMed: 7993409]
  • Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70:206–15. [PubMed: 12111766]
  • Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447–52. [PMC free article: PMC2867259] [PubMed: 20194891]
  • Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet JF, Grevent D, Beuzard Y, Chrétien S, Lefebvre T, Ross RW, Negre O, Veres G, Sandler L, Soni S, de Montalembert M, Blanche S, Leboulch P, Cavazzana M. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848–855. [PubMed: 28249145]
  • Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin North Am. 2005;19:917–28. [PubMed: 16214652]
  • Rogers ZR, Wang WC, Luo Z, Lyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood. 2011;117:2614–7. [PMC free article: PMC3062353] [PubMed: 21217080]
  • Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG 6th, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR. Walk-PHASST Investigators. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011;124:1452–60. [PMC free article: PMC3183314] [PubMed: 21900080]
  • Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322:1839–42. [PubMed: 19056937]
  • Sankaran VG, Xu J, Byron R, Greisman HA, Fisher C, Weatherall DJ, Sabath DE, Groudine M, Orkin SH, Premawardhena A, Bender MA. A functional element necessary for fetal hemoglobin silencing. N Engl J Med. 2011;365:807–14. [PMC free article: PMC3174767] [PubMed: 21879898]
  • Sankaran VG, Xu J, Orkin SH. Transcriptional silencing of fetal hemoglobin by BCL11A. Ann N Y Acad Sci. 2010;1202:64–8. [PubMed: 20712774]
  • Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol. 2008;141:126–9. [PubMed: 18324975]
  • Scharenberg AM, Duchateau P, Smith J. Genome engineering with TAL-effector nucleases and alternative modular nuclease technologies. Curr Gene Ther. 2013;13:291–303. [PubMed: 23888878]
  • Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56:1109–11. [PubMed: 11320190]
  • Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013;3:a011783. [PMC free article: PMC3784812] [PubMed: 23813607]
  • Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med. 2013;19:291–4. [PMC free article: PMC5512162] [PubMed: 23416702]
  • Smith JA, Espeland M, Bellevue R, Bonds D, Brown AK, Koshy M. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol. 1996;87:199–204. [PubMed: 8559523]
  • Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129:465–81. [PubMed: 15877729]
  • Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. Curr Opin Hematol. 2006;13:131–6. [PubMed: 16567954]
  • Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer. 2012;59:365–71. [PMC free article: PMC3374046] [PubMed: 22517797]
  • Tarini BA, Brooks MA, Bundy DG. A policy impact analysis of the mandatory NCAA sickle cell trait screening program. Health Serv Res. 2012;47:446–61. [PMC free article: PMC3288389] [PubMed: 22150647]
  • Thompson AA. Sickle cell trait testing and athletic participation: a solution in search of a problem? Hematology Am Soc Hematol Educ Program. 2013;2013:632–7. [PubMed: 24319243]
  • Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012;120:4304–10. [PMC free article: PMC3507142] [PubMed: 22915643]
  • Tisdale JF, Eapen M, Saccardi R. HCT for nonmalignant disorders. Biol Blood Marrow Transplant. 2013;19:S6–9. [PubMed: 23104188]
  • Vichinsky E. Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology Am Soc Hematol Educ Program. 2012;2012:271–5. [PubMed: 23233591]
  • Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322:1617–21. [PubMed: 2342522]
  • Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol. 2008;199:125.e1–5. [PubMed: 18533123]
  • Walters MC. Update of hematopoietic cell transplantation for sickle cell disease. Curr Opin Hematol. 2015;22:227–33. [PMC free article: PMC5037959] [PubMed: 25767957]
  • Walters MC, De Castro LM, Sullivan KM, Krishnamurti L, Kamani N, Bredeson C, Neuberg D, Hassell KL, Farnia S, Campbell A, Petersdorf E. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016;22:207–11. [PMC free article: PMC5031360] [PubMed: 26500093]
  • Wang WC, Gallagher DM, Pegelow CH, Wright EC, Vichinsky EP, Abboud MR, Moser FG, Adams RJ. Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. J Pediatr Hematol Oncol. 2000;22:335–9. [PubMed: 10959904]
  • Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013;132:677–83. [PMC free article: PMC4074648] [PubMed: 23999955]
  • Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW., BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663–72. [PMC free article: PMC3133619] [PubMed: 21571150]
  • Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115:5300–11. [PMC free article: PMC2902131] [PubMed: 20223921]
  • Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390:311–323. [PubMed: 28159390]
  • Ware RE, Helms RW. SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119:3925–32. [PMC free article: PMC3350359] [PubMed: 22318199]
  • Webb J, Kwiatkowski JL. Stroke in patients with sickle cell disease. Expert Rev Hematol. 2013;6:301–16. [PubMed: 23782084]
  • Wilber A, Hargrove PW, Kim YS, Riberdy JM, Sankaran VG, Papanikolaou E, Georgomanoli M, Anagnou NP, Orkin SH, Nienhuis AW, Persons DA. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood. 2011;117:2817–26. [PMC free article: PMC3062294] [PubMed: 21156846]
  • Wood DK, Soriano A, Mahadevan L, Higgins JM, Bhatia SN. A biophysical indicator of vaso-occlusive risk in sickle cell disease. Sci Transl Med. 2012;4:123ra26. [PMC free article: PMC3633235] [PubMed: 22378926]
  • Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14:183–90. [PMC free article: PMC2892972] [PubMed: 17414205]
  • Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, Fujiwara Y, Ebert BL, Tucker PW, Orkin SH. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 2011;334:993–6. [PMC free article: PMC3746545] [PubMed: 21998251]
  • Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48. [PubMed: 25203083]
  • Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120:528–37. [PMC free article: PMC3401213] [PubMed: 22563085]
  • Zarrouk V, Habibi A, Zahar JR, Roudot-Thoraval F, Bachir D, Brun-Buisson C, Legrand P, Godeau B, Galacteros F, Lesprit P. Bloodstream infection in adults with sickle cell disease: association with venous catheters, Staphylococcus aureus, and bone-joint infections. Medicine (Baltimore). 2006;85:43–8. [PubMed: 16523052]
  • Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127:801–9. [PMC free article: PMC4760086] [PubMed: 26758915]
Copyright © 1993-2021, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source ( and copyright (© 1993-2021 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK1377PMID: 20301551


Tests in GTR by Gene

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed
  • Gene
    Locus Links

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...